Literature DB >> 12524665

Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults.

Arthur Weltman1, Jean Pierre Despres, Jody L Clasey, Judy Y Weltman, Laurie Wideman, Jill Kanaley, James Patrie, Jean Bergeron, Michael O Thorner, Claude Bouchard, Mark L Hartman.   

Abstract

We examined the relationship between abdominal visceral fat (AVF) and plasma concentrations of lipids and lipoproteins in 19 females (F) (not on estrogen) and 31 males (M) over the age of 60 (age = 66.8 years). In addition, the effects of growth hormone (GH) release, fitness (Vo(2) peak), insulin, and glucose concentrations (both fasting and in response to an oral glucose tolerance test) on lipids were examined. Subjects were categorized by low (L) and high (H) AVF (L < 130 cm(2), H > 130 cm(2)), fat mass (FM) (above or below median value), and AVF corrected for fat mass. Factorial analysis of variance (ANOVA) showed that when subjects were divided by AVF and FM, similar results were observed with H > L (P <.05) for very-low-density lipoprotein-cholesterol (VLDL-C), triglycerides (TG), VLDL-TG, apolipoprotein (apo)-B, apo-B VLDL, cholesterol (Chol)/high-density lipoprotein (HDL), LDL/HDL, apoB/A1 and L > H for HDL, HDL(2), HDL(3), apo A1, and LDL/apo-B LDL. Gender differences were also observed with F > M for Chol, LDL, HDL, and HDL(2). When AVF was corrected for FM, these gender differences were still present. After correcting for FM, differences remained between H and L AVF groups for VLDL, TG, VLDL-TG, apo-B, apo-B LDL, apo-B VLDL, apoB/A1 (P <.05). Twenty-four hour integrated GH concentration (IGHC) was inversely related to VLDL, TG, VLDL TG, LDL TG, apoB, apoB VLDL, apoB LDL, Chol/HDL, LDL/HDL, and apoB/A1 in F, but not M (P <.05). Vo(2) peak was directly related to Chol, LDL, HDL(3), and apoB LDL with stronger relationships observed in F. Fasting insulin was related to lipids and lipoproteins in both men and women. These data suggest that, in older adults, elevated levels of AVF, FM, and AVF corrected for FM are associated with unfavorable lipid-lipoprotein profiles and extend similar findings reported in younger males and females with elevated AVF. These data also support previous findings indicating that AVF is a primary determinant of GH release. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524665     DOI: 10.1053/meta.2003.50007

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

Review 1.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Authors:  Ralf Nass; Suzan S Pezzoli; Mary Clancy Oliveri; James T Patrie; Frank E Harrell; Jody L Clasey; Steven B Heymsfield; Mark A Bach; Mary Lee Vance; Michael O Thorner
Journal:  Ann Intern Med       Date:  2008-11-04       Impact factor: 25.391

3.  Effects of continuous versus intermittent exercise, obesity, and gender on growth hormone secretion.

Authors:  Arthur Weltman; Judy Y Weltman; Dee Dee Watson Winfield; Kirsten Frick; James Patrie; Petra Kok; Daniel M Keenan; Glenn A Gaesser; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2008-09-09       Impact factor: 5.958

4.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

5.  Relative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls.

Authors:  M Russell; M Bredella; P Tsai; N Mendes; K K Miller; A Klibanski; M Misra
Journal:  J Clin Endocrinol Metab       Date:  2009-05-12       Impact factor: 5.958

Review 6.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.

Authors:  Darlene E Berryman; Camilla A M Glad; Edward O List; Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2013-04-09       Impact factor: 43.330

7.  Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion.

Authors:  A L Utz; A Yamamoto; P Sluss; J Breu; K K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

8.  GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90.

Authors:  John D Carmichael; Ann Danoff; Daniela Milani; Ronenn Roubenoff; Martin L Lesser; Elayne Livote; Richard E Reitz; Steven Ferris; David L Kleinberg
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

Review 9.  The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.

Authors:  Moira S Lewitt
Journal:  Biochem Insights       Date:  2017-04-20

10.  Determination of Cutoff Values for DEXA-Based Body Composition Measurements for Determining Metabolic and Cardiovascular Health.

Authors:  Pierre-Olivier Lang; Christophe Trivalle; Thomas Vogel; Jacques Proust; Jean-Pierre Papazyan; Moustapha Dramé
Journal:  Biores Open Access       Date:  2015-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.